Skip to main content

Report Under Canada’s Fighting Against Forced Labour and Child Labour in Supply Chains Act

For the Year Ended December 31, 2023.

This report (the “Report”) for the year ended December 31, 2023, is prepared in accordance with the Fighting Against Forced Labour and Child Labour in Supply Chains Act (the “Act”) and is made on behalf of Boston Scientific Corporation (“BSC”), Boston Scientific Limited (“BSL”) and Baylis Medical Company Inc. (“Baylis”, collectively, “Boston Scientific”, “us”, “we” or “our”). BSL and Baylis are Canadian wholly owned subsidiaries of BSC, with headquarters in Marlborough, Massachusetts.

The Act requires us to state actions we took to prevent and reduce the risk of forced labour or child labour with our operations and supply chain. This report incorporates by reference the 2023 UK Modern Slavery Statement (“2023 Modern Slavery Statement”) already published by Boston Scientific Corporation, which is appended below (Annex A).

Structure, activities and supply chain.

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. We are a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of medical specialties. These products are generally sold directly or through distributors and agents to hospitals or physicians, making Boston Scientific the final step in the supply chain prior to these products reaching the end customer. Additional details about the operations of the Entities (as defined in the Act) in Canada follows below:

  • BSL is engaged in the import and distribution of medical devices in Canada, in the fields of Endoscopy, Urology, Neuromodulation, Cardiology (including Interventional Cardiology Therapies, Watchman, Cardiac Rhythm Management, and Electrophysiology), and Peripheral Interventions. BSL currently employs 241 people in Canada and is headquartered in Brampton, Ontario. BSL’s supply chain primarily reflects procurement of medical devices (finished goods) from affiliated entities within Boston Scientific’s group.
  • Baylis was acquired by BSC in February 2022. Baylis operates in the fields of Cardiology and Electrophysiology, primarily researching, designing, and manufacturing medical devices to enable transseptal access to the left side of the heart, with such products manufactured by Baylis in Canada and at an affiliated Boston Scientific’s manufacturing site in Costa Rica. Baylis previously sold its medical devices directly to health care providers in Canada, United States of America, France, Germany, and the UK and through channel partners to Japan and other parts of the world, though in February 2023, the sale of Baylis’s products transitioned to Boston Scientific’s global distribution network of direct sales subsidiaries and channel partners. Baylis employs around 708 people and is headquartered in Mississauga, Ontario.
  • Baylis’ supply chain includes the procurement of metals, electronics, plastics, resins, chemicals, packaging and finished medical goods from component and sub-component manufacturers and distributors. Baylis is in the process of integrating its operations and procurement activities with the broader Boston Scientific group. Therefore, in 2023, Baylis continued to procure some goods and services based on its previously existing procedures while continuing to integrate its supply chain into Boston Scientific’s. Baylis expects its operations to be fully integrated within Boston Scientific’s global supply chain by the end of 2025.

Policies, due diligence processes, risk assessment, training, and assessing effectiveness.

Our regional operations in Canada are structured to align with Boston Scientific’s global ethics and compliance policies. We procure goods and services in alignment with Boston Scientific’s global supply chain framework, which includes our Supplier Code of Conduct, supplier risk assessment, audits, due diligence procedures and employee training.

See the attached 2023 Modern Slavery Statement (included in Annex A) for detailed information regarding our global policies, due diligence, risk assessment process for suppliers, employee training, and how we assess our effectiveness in relation to the risk of forced and child labour in our supply chains.


In 2023, we have not identified any forced or child labour in our activities or supply chains. Therefore, no measures were taken to remediate any instances of forced or child labour, and there has been no resulting loss of income to the most vulnerable families.


This report was approved pursuant to subparagraph 11(4)(b)(ii) of the Fighting Against Forced Labour and Child Labour in Supply Chains Act, by the board of directors of Boston Scientific Corporation.

In accordance with the requirements of the Act, and in particular section 11 thereof, I attest that I have reviewed the information contained in the report for the entity or entities listed above.

Based on my knowledge, and having exercised reasonable diligence, I attest that the information in the report is true, accurate and complete in all material respects for the purposes of the Act, for the reporting year listed above.

This statement has been approved by the Board of Directors of Boston Scientific Corporation. This report is made on behalf of Boston Scientific Corporation and the group entities in Canada: Baylis Medical Company Inc, with headquarters in Mississauga-ON, and Boston Scientific Limited, with headquarters in Brampton-ON.